Printer Friendly

PRINCETON DIAGNOSTIC LABORATORIES OF AMERICA REORGANIZES ITS SUBSIDIARY

PRINCETON DIAGNOSTIC LABORATORIES OF AMERICA REORGANIZES ITS SUBSIDIARY
 SOUTH PLAINFIELD, N.J., July 8 /PRNewswire/ -- Princeton Diagnostic Laboratories of America, Inc. (AMEX: PDA) today announced a reorganization of its subsidiary, Psychiatric Diagnostic Laboratories of America (PDLA). Fred McBee and Dr. Wade Smith have been hired to handle the company's psychiatric sales, marketing and hospital services.
 Dr. Carlton Turner, president and CEO, stated, "Mr. Fred McBee has been exceedingly successful in managing and developing specialty lab programs at International Clinical Laboratory (ICL), Med Express Laboratories, and most recently with National Psychopharmacology Laboratory (NPL)." McBee stated, "I am pleased to join the only laboratory specializing in psychiatric hospital services certified by the College of American Pathologist (CAP)."
 Smith, Pharmacy D., brings to PDLA, a unique background in consultative selling from Eli Lilly and NPL. Turner stated, "Dr. Smith's detailed knowledge of drugs used by psychiatric hospitals, clinics and psychiatrists will enable PDLA to refine and provide precise laboratory services required by these groups and managed care contractors."
 Psychiatric Diagnostic Laboratories of America, Inc., was established in 1978 by psychiatrists for psychiatrists and is a full- service laboratory specializing in the unique needs of the clinical psychiatric community. PDLA has been at the forefront of biopsychiatry, providing sophisticated laboratory tests to help psychiatrists accurately identify disorders, select appropriate therapy, and monitor therapeutic effectiveness.
 PDLA processes toxicology samples under Federal Guidelines (NIDA), for pre-employment and random sampling of drug-free workplace programs. In addition, PDLA provides specialized clinical testing relating to the detection and monitoring of the treatment of psychiatric disorders, drug abuse, and other illnesses for private psychiatric hospitals, psychiatrists, other clinical laboratories, associations, and operating companies. These tests are used by major corporations, including 12 percent of the top 50 industrial companies of the Fortune 500, for diagnostic pre-employment screening.
 -0- 7/8/92
 /CONTACT: Warren Majek of Princeton Diagnostic Laboratories of America, 908-769-8500/
 (PDA) CO: Princeton Diagnostic Laboratories of America, Inc. ST: New Jersey IN: HEA SU: RCN


CK-OS -- NY042 -- 7424 07/08/92 12:49 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 8, 1992
Words:335
Previous Article:SOMATIX NAMES SOFRONIEW TO HEAD NEURAL PROGRAM
Next Article:DIAMOND-STAR MOTORS NAMES NEW GENERAL MANAGER
Topics:


Related Articles
PDLA ANNOUNCES RESIGNATION OF DIRECTOR AND ELECTION OF NEW CHAIRMAN OF THE BOARD
PRINCETON DIAGNOSTIC LABORATORIES REPORTS RESULTS
WARREN N. MAJEK JOINS PRINCETON DIAGNOSTIC LABORATORIES OF AMERICA AS GENERAL MANAGER SECRETARY/TREASURER
PRINCETON DIAGNOSTIC LABORATORIES OF AMERICA, INC. APPOINTS MCBEE VP
PRINCETON DIAGNOSTIC LABORATORIES OF AMERICA ANNOUNCES SALE OF FACILITY
PRINCETON DIAGNOSTIC LABORATORIES OF AMERICA, INC. SHAREHOLDERS APPROVE MERGER WITH EDITEK, INC.
MICHAEL TERRETTI JOINS PDLA, INC. AS VICE PRESIDENT AND GENERAL MANAGER
DRUG TESTING EVOLUTION DESCRIBED AT EDITEK ANNUAL SHAREHOLDER MEETING
EDITEK, INC. ENGAGES INVESTMENT BANKER FOR ITS ACQUISITIONS PROGRAM
EDITEK, INC. REPORTS THIRD QUARTER RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters